Articles related to FDA

Unprecedented eye drop recalls have led to significant health risks, including four fatalities. Learn more to ensure that you guide your patients towards safer, FDA-approved alternatives.

Discover how Miebo, supported by phase 3 clinical trials, offers a unique approach to dry eye disease by specifically targeting tear evaporation.

Stay informed with the FDA’s latest update on temozolomide labeling, which includes new indications and safety guidelines crucial for treating specific brain tumors.

Explore the FDA-approved Tyruko, a biosimilar to Tysabri, which has shown comparable safety and efficacy in phase 3 clinical trials for treating relapsing forms of MS.

Discover how Elrexfio’s conditional FDA approval could redefine the treatment landscape for patients with difficult-to-treat multiple myeloma. Dive into the promising clinical trial results and understand its potential impact on your practice.

Discover how AOC 1044’s recent FDA orphan drug designation could revolutionize the treatment landscape for Duchenne muscular dystrophy patients with exon 44 mutations. Stay tuned for upcoming results from the EXPLORE44 trial.